Background: The pathogenesis of acne vulgaris is multifactorial, and therapy can be directed at many of these factors, singly or in combination. There are different modalities of treatment of active acne vulgaris but ...Background: The pathogenesis of acne vulgaris is multifactorial, and therapy can be directed at many of these factors, singly or in combination. There are different modalities of treatment of active acne vulgaris but they are often long lasting which could not be accepted by many patients. Objective: To evaluate the effectiveness, long term efficacy and safety of chemical peeling using 35% TCA solution in the treatment of active acne vulgaris. Patients and Methods:This clinical, interventional, therapeutic study was done at the Department of Dermatology—Baghdad Teaching Hospital during the period from January 2012 to March 2013. Eighteen patients with active acne vulgaris were included in this study, 10 (55.6%) females and 8 (44.4%) males. Their ages ranged from 15 to 35 (21.56 ± 5.501) years. Twelve patients were associated with acne scars. History and dermatological examination were performed for all patients regarding all demographic points related to the disease. Chemical peeling with 35% TCA used one session regarding active acne vulgaris and three sessions in patients with associated scarring. Scoring for active acne vulgaris and acne scar was done for each case before and after peeling to evaluate the severity of acne lesions and scarring. All patients were with Fitzpatrick’s skin types III and IV. Patients were followed up every two weeks for 12 weeks after starting therapy and every 4 weeks for 12 weeks after stopping the treatment to watch improvement, side effects and relapse. Results: Scoring for active acne vulgaris including papules and pustules showed highly statistically significant reduction after 2 weeks of therapy (p Conclusions: Chemical peeling by TCA 35% is a cost-effective mode of therapy for active acne vulgaris and acne scar with low down time in patients with dark complexion.展开更多
目的:探讨窄谱强脉冲光联合重组人表皮生长因子凝胶治疗面部痤疮瘢痕的临床疗效。方法:选取2017年2月-2018年3月笔者医院收治的80例面部痤疮瘢痕患者,随机分为对照组与观察组,每组40例。对照组给予窄谱强脉冲光照射治疗,观察组在对照组...目的:探讨窄谱强脉冲光联合重组人表皮生长因子凝胶治疗面部痤疮瘢痕的临床疗效。方法:选取2017年2月-2018年3月笔者医院收治的80例面部痤疮瘢痕患者,随机分为对照组与观察组,每组40例。对照组给予窄谱强脉冲光照射治疗,观察组在对照组基础上给予重组人表皮生长因子凝胶涂抹。对比两组临床疗效,比较结痂持续时间、痂皮脱落时间及治疗后痤疮瘢痕权重评分(clinical evaluation scale for acnescarring,ECCA),观察不良反应发生情况及治疗前后的痤疮特异性生活质量量表(Acne-specific Quality of Life Questionnaire,Acne-QOL)评分,并统计随访3个月患者复发率。结果:两组临床疗效等级分布比较差异具有统计学意义(P<0.05),观察组总有效率高于对照组,差异具有统计学意义(P<0.05);观察组结痂持续时间与痂皮脱落时间均短于对照组,观察组治疗后ECCA评分小于对照组,差异均具有统计学意义(P<0.05);观察组治疗后总不良反应发生率低于对照组,差异具有统计学意义(P<0.05);两组治疗后Acne-QOL量表中社会功能、自我认知、情感功能及痤疮症状评分均高于治疗前,观察组治疗后Acne-QOL量表各维度评分均高于对照组,差异均具有统计学意义(P<0.05);随访3个月,两组复发率差异无统计学意义(P>0.05)。结论:窄谱强脉冲光联合重组人表皮生长因子凝胶虽未能有效预防痤疮瘢痕复发,但可明显改善面部痤疮瘢痕患者临床症状,提高疗效,缩短结痂与痂皮脱落时间,并可减轻不良反应及提高患者生活质量。展开更多
目的探讨点阵CO2激光治疗痤疮凹陷性瘢痕的疗效及安全性。方法以Dreno瘢痕性质作为诊断标准纳入83例患者,采用10600 nm CO2激光进行治疗,选用点阵、脉冲模式,点距1.1,横距8.8,纵距8.8,能量30~40 m J,扫描2遍,穿透深度450~600μm,治疗1...目的探讨点阵CO2激光治疗痤疮凹陷性瘢痕的疗效及安全性。方法以Dreno瘢痕性质作为诊断标准纳入83例患者,采用10600 nm CO2激光进行治疗,选用点阵、脉冲模式,点距1.1,横距8.8,纵距8.8,能量30~40 m J,扫描2遍,穿透深度450~600μm,治疗1次为一疗程。术后局部外用1周重组牛碱性成纤维细胞生长因子凝胶以促进修复。根据ECCA评分表评分及计算总分,计算疗效指数,并按基本治愈、显效、有效、无效进行疗效判定。结果完成1、3、6个月随访的患者分别为:83例(100%)、77例(92.8%)、65例(78.3%)。ECCA总分数治疗前为(62.5±4.6)分;治疗后1个月为(50.1±6.7)分;治疗后3个月为(35.5±7.9)分;治疗后6个月为(36.5±8.5)分。治疗后1、3、6个月ECCA总分低于治疗前(P<0.05);治疗后3、6个月ECCA总分低于治疗后1个月(P<0.05);治疗后3个月与治疗后6个月相比,其差异无统计学意义。所有患者不良反应均为暂时的且可耐受。结论采用点阵CO2激光治疗痤疮凹陷性瘢痕疗效确切,安全性好,值得临床推广应用。展开更多
文摘Background: The pathogenesis of acne vulgaris is multifactorial, and therapy can be directed at many of these factors, singly or in combination. There are different modalities of treatment of active acne vulgaris but they are often long lasting which could not be accepted by many patients. Objective: To evaluate the effectiveness, long term efficacy and safety of chemical peeling using 35% TCA solution in the treatment of active acne vulgaris. Patients and Methods:This clinical, interventional, therapeutic study was done at the Department of Dermatology—Baghdad Teaching Hospital during the period from January 2012 to March 2013. Eighteen patients with active acne vulgaris were included in this study, 10 (55.6%) females and 8 (44.4%) males. Their ages ranged from 15 to 35 (21.56 ± 5.501) years. Twelve patients were associated with acne scars. History and dermatological examination were performed for all patients regarding all demographic points related to the disease. Chemical peeling with 35% TCA used one session regarding active acne vulgaris and three sessions in patients with associated scarring. Scoring for active acne vulgaris and acne scar was done for each case before and after peeling to evaluate the severity of acne lesions and scarring. All patients were with Fitzpatrick’s skin types III and IV. Patients were followed up every two weeks for 12 weeks after starting therapy and every 4 weeks for 12 weeks after stopping the treatment to watch improvement, side effects and relapse. Results: Scoring for active acne vulgaris including papules and pustules showed highly statistically significant reduction after 2 weeks of therapy (p Conclusions: Chemical peeling by TCA 35% is a cost-effective mode of therapy for active acne vulgaris and acne scar with low down time in patients with dark complexion.
文摘目的:探讨窄谱强脉冲光联合重组人表皮生长因子凝胶治疗面部痤疮瘢痕的临床疗效。方法:选取2017年2月-2018年3月笔者医院收治的80例面部痤疮瘢痕患者,随机分为对照组与观察组,每组40例。对照组给予窄谱强脉冲光照射治疗,观察组在对照组基础上给予重组人表皮生长因子凝胶涂抹。对比两组临床疗效,比较结痂持续时间、痂皮脱落时间及治疗后痤疮瘢痕权重评分(clinical evaluation scale for acnescarring,ECCA),观察不良反应发生情况及治疗前后的痤疮特异性生活质量量表(Acne-specific Quality of Life Questionnaire,Acne-QOL)评分,并统计随访3个月患者复发率。结果:两组临床疗效等级分布比较差异具有统计学意义(P<0.05),观察组总有效率高于对照组,差异具有统计学意义(P<0.05);观察组结痂持续时间与痂皮脱落时间均短于对照组,观察组治疗后ECCA评分小于对照组,差异均具有统计学意义(P<0.05);观察组治疗后总不良反应发生率低于对照组,差异具有统计学意义(P<0.05);两组治疗后Acne-QOL量表中社会功能、自我认知、情感功能及痤疮症状评分均高于治疗前,观察组治疗后Acne-QOL量表各维度评分均高于对照组,差异均具有统计学意义(P<0.05);随访3个月,两组复发率差异无统计学意义(P>0.05)。结论:窄谱强脉冲光联合重组人表皮生长因子凝胶虽未能有效预防痤疮瘢痕复发,但可明显改善面部痤疮瘢痕患者临床症状,提高疗效,缩短结痂与痂皮脱落时间,并可减轻不良反应及提高患者生活质量。
文摘目的探讨点阵CO2激光治疗痤疮凹陷性瘢痕的疗效及安全性。方法以Dreno瘢痕性质作为诊断标准纳入83例患者,采用10600 nm CO2激光进行治疗,选用点阵、脉冲模式,点距1.1,横距8.8,纵距8.8,能量30~40 m J,扫描2遍,穿透深度450~600μm,治疗1次为一疗程。术后局部外用1周重组牛碱性成纤维细胞生长因子凝胶以促进修复。根据ECCA评分表评分及计算总分,计算疗效指数,并按基本治愈、显效、有效、无效进行疗效判定。结果完成1、3、6个月随访的患者分别为:83例(100%)、77例(92.8%)、65例(78.3%)。ECCA总分数治疗前为(62.5±4.6)分;治疗后1个月为(50.1±6.7)分;治疗后3个月为(35.5±7.9)分;治疗后6个月为(36.5±8.5)分。治疗后1、3、6个月ECCA总分低于治疗前(P<0.05);治疗后3、6个月ECCA总分低于治疗后1个月(P<0.05);治疗后3个月与治疗后6个月相比,其差异无统计学意义。所有患者不良反应均为暂时的且可耐受。结论采用点阵CO2激光治疗痤疮凹陷性瘢痕疗效确切,安全性好,值得临床推广应用。
